Current concepts on cytomegalovirus infection after liver transplantation

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 9

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

601

HTML

3282

Figures (1-3)

206

Tables (1-4)

212

Sum=4301

Sep 27, 2010 (publication date) through Nov 26, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Hepatol. Sep 27, 2010; 2(9): 325-336
Published online Sep 27, 2010. doi: 10.4254/wjh.v2.i9.325

Table 4 Currently available antiviral drugs for cytomegalovirus prophylaxis and treatment in liver transplant recipients

Drug	Route	Usual adult prophylaxis dose	Usual adult treatment dose	Comments on use and major toxicity
Ganciclovir	Intravenous	5 mg/kg once daily	5 mg/kg twice daily	Intravenous access; leukopenia
Ganciclovir	Oral	1 g three times daily	Not applicable	Low oral bioavailability; high pill burden
Valganciclovir	Oral	900 mg once daily	900 mg twice daily	Ease of administration; leukopenia

Citation: Lee SO, Razonable RR. Current concepts on cytomegalovirus infection after liver transplantation. World J Hepatol 2010; 2(9): 325-336
URL: https://www.wjgnet.com/1948-5182/full/v2/i9/325.htm
DOI: https://dx.doi.org/10.4254/wjh.v2.i9.325